Amberstone Biosciences, a Laguna Hills, CA-based biotherapeutics company with unique expertise in conditionally active immunotherapeutics, closed a $12m Series A financing round.
The round was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with participation from ChangRong Capital, Lifespan Investments and existing shareholders.
The company will use the proceeds from the financing to advance its tumor microenvironment activated therapeutic programs including bispecific antibodies and immunocytokines to the investigational new drug application (IND) enabling stage.
Incorporated in 2018 by President and CEO George Wu, PhD., Amberstone Biosciences is a biotherapeutics company developing a novel class of targeted and conditionally active immunotherapeutics to treat solid tumor cancers and other diseases. Amberstone Biosciences’ pipeline is driven by an innovative high-throughput single-cell functional discovery platform and strong expertise in an interdisciplinary field of biology, engineering, and therapeutic development.